These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 16703976)

  • 21. Ziconotide: A rapid detoxification protocol for the conversion from intrathecal morphine--the Raffaeli Detoxification Model.
    Raffaeli W; Righetti D; Sarti D; Balestri M; Ferioli I; Monterubbianesi MC; Caminiti A
    J Opioid Manag; 2011; 7(1):21-6. PubMed ID: 21434581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice.
    Alicino I; Giglio M; Manca F; Bruno F; Puntillo F
    Pain; 2012 Jan; 153(1):245-249. PubMed ID: 22082570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ziconotide: an update and review.
    Williams JA; Day M; Heavner JE
    Expert Opin Pharmacother; 2008 Jun; 9(9):1575-83. PubMed ID: 18518786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ziconotide: a clinical update and pharmacologic review.
    Pope JE; Deer TR
    Expert Opin Pharmacother; 2013 May; 14(7):957-66. PubMed ID: 23537340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intrathecal Ziconotide: Dosing and Administration Strategies in Patients With Refractory Chronic Pain.
    McDowell GC; Pope JE
    Neuromodulation; 2016 Jul; 19(5):522-32. PubMed ID: 26856969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of Low Dose Ziconotide as First-Line Intrathecal Monotherapy.
    Prusik J; Argoff C; Peng S; Pilitsis JG
    Neuromodulation; 2017 Jun; 20(4):386-391. PubMed ID: 27492135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide as Firstline Options.
    Deer TR; Pope JE; Hanes MC; McDowell GC
    Pain Med; 2019 Apr; 20(4):784-798. PubMed ID: 30137539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aseptic arachnoiditis in a patient treated with intrathecal morphine infusion: symptom resolution on switch to ziconotide.
    Codipietro L; Maino P
    Neuromodulation; 2015 Apr; 18(3):217-20; discussion 220. PubMed ID: 24945709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ziconotide combination intrathecal therapy: rationale and evidence.
    Wallace MS; Rauck RL; Deer T
    Clin J Pain; 2010 Sep; 26(7):635-44. PubMed ID: 20639730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ziconotide for treatment of severe chronic pain.
    Schmidtko A; Lötsch J; Freynhagen R; Geisslinger G
    Lancet; 2010 May; 375(9725):1569-77. PubMed ID: 20413151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Considerations and methodology for trialing ziconotide.
    Burton AW; Deer TR; Wallace MS; Rauck RL; Grigsby E
    Pain Physician; 2010; 13(1):23-33. PubMed ID: 20119460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bolus intrathecal injection of ziconotide (Prialt®) to evaluate the option of continuous administration via an implanted intrathecal drug delivery (ITDD) system: a pilot study.
    Mohammed SI; Eldabe S; Simpson KH; Brookes M; Madzinga G; Gulve A; Baranidharan G; Radford H; Crowther T; Buchser E; Perruchoud C; Batterham AM
    Neuromodulation; 2013; 16(6):576-81; discussion 582. PubMed ID: 23205907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intrathecal ziconotide: a review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics.
    Sanford M
    CNS Drugs; 2013 Nov; 27(11):989-1002. PubMed ID: 23999971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonclinical safety of ziconotide: an intrathecal analgesic of a new pharmaceutical class.
    Skov MJ; Beck JC; de Kater AW; Shopp GM
    Int J Toxicol; 2007; 26(5):411-21. PubMed ID: 17963128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term Outcomes Using Intrathecal Drug Delivery Systems in Complex Regional Pain Syndrome.
    Herring EZ; Frizon LA; Hogue O; Mejia JU; Rosenquist R; Bolash RB; Machado AG; Nagel SJ
    Pain Med; 2019 Mar; 20(3):515-520. PubMed ID: 29889241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ziconotide.
    Lyseng-Williamson KA; Perry C
    CNS Drugs; 2006; 20(4):331-8; discussion 339-41. PubMed ID: 16599651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Relationship Between the Mechanisms of Action and Safety Profiles of Intrathecal Morphine and Ziconotide: A Review of the Literature.
    Webster LR
    Pain Med; 2015 Jul; 16(7):1265-77. PubMed ID: 25645109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ziconotide: can we use it in palliative care?
    Prommer EE
    Am J Hosp Palliat Care; 2005; 22(5):369-74. PubMed ID: 16225359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute rhabdomyolysis in a patient with long-term exposure to intrathecal ziconotide: a case report.
    Horazeck C; Huh AS; Huh BK
    Pain Pract; 2015 Mar; 15(3):E34-9. PubMed ID: 25565390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ziconotide infusion for severe chronic pain: case series of patients with neuropathic pain.
    Wermeling DP; Berger JR
    Pharmacotherapy; 2006 Mar; 26(3):395-402. PubMed ID: 16503720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.